AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

计划入组 10 人 · 首次发布于 2013 年 10 月 22 日

Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure

计划入组 5 人 · 首次发布于 2007 年 9 月 26 日

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

计划入组 12 人 · 首次发布于 2014 年 12 月 17 日

Oral SERCA2a Activators

AAV-204

AAV-qC10

Abeona Therapeutics

United States

Asklepios Biopharmaceutical, Inc.

United States

4D Molecular Therapeutics

United States

Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Medera Showcases Human Mini-Heart Technology Breakthroughs at ISSCR 2025, Advancing Gene Therapy Clinical Trials

Medera Treats First Patient in Groundbreaking Gene Therapy Trial for Duchenne Muscular Dystrophy Heart Failure